Source: Scottish Medicines Consortium (SMC)
Area: Evidence > Drug Specific Reviews
Following consideration of a resubmission, the Scottish Medicines Consortium (SMC) still does not recommend dexamethasone intravitreal implant (Ozurdex®) for use within NHS Scotland for the treatment of adult patients with macular oedema following either branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO).
The drug advice (see link below) notes that the 700mcg Ozurdex® implant was superior to sham in two Phase III studies, in terms of the proportion of patients with a best corrected visual (Read more...)
Uncategorized